Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.

Autor: Beaumont JL; Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Salsman JM; Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.; Comprehensive Cancer Center at Wake Forest Baptist, Winston-Salem, North Carolina., Diaz J; Novartis Pharma AG, Basel, Switzerland., Deen KC; GlaxoSmithKline, Collegeville, Pennsylvania., McCann L; GlaxoSmithKline, Collegeville, Pennsylvania., Powles T; Barts Cancer Institute, London, United Kingdom., Hackshaw MD; Novartis Pharma Services AG, Basel, Switzerland., Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, New York., Cella D; Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.

Publikováno v: Cancer [Cancer] 2016 Apr 01; Vol. 122 (7), pp. 1108-15. Date of Electronic Publication: 2016 Jan 27.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.

Autor: Xu CF; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK., Johnson T; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK., Garcia-Donas J; 1] Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Calle de Oña 10, Madrid 28050, Spain [2] Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Sternberg CN; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Circonvallazione Gianicolense 87, Rome 00152, Italy., Davis ID; Monash University Eastern Health Clinical School, 5 Arnold Street, Victoria 3128, Australia., Bing N; GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA., Deen KC; GlaxoSmithKline, 250 S. Collegeville Road, Collegeville, PA 19426-0989, USA., Xue Z; GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA., McCann L; GlaxoSmithKline, 250 S. Collegeville Road, Collegeville, PA 19426-0989, USA., Esteban E; 1] Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Calle de Oña 10, Madrid 28050, Spain [2] Hospital Universitario Central de Asturias, Calle Carretera de Rubín, Oviedo 33011, Spain., Whittaker JC; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK., Spraggs CF; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK., Rodríguez-Antona C; Spanish National Cancer Research Centre and ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Calle de Melchor Fernández Almagro 3, Madrid 28029, Spain., Pandite LN; GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA., Motzer RJ; Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Publikováno v: British journal of cancer [Br J Cancer] 2015 Mar 31; Vol. 112 (7), pp. 1190-8. Date of Electronic Publication: 2015 Mar 31.

The V2 domain of HIV gp120 mimics an interaction between CD4 and integrin ⍺4β7.

Autor: Van Ryk, Donald¹ (AUTHOR), Vimonpatranon, Sinmanus^1,2 (AUTHOR), Hiatt, Joe¹ (AUTHOR), Ganesan, Sundar³ (AUTHOR), Chen, Nathalie¹ (AUTHOR), McMurry, Jordan¹ (AUTHOR), Garba, Saadiq¹ (AUTHOR), Min, Susie¹ (AUTHOR), Goes, Livia R.^1,4 (AUTHOR), Girard, Alexandre¹ (AUTHOR), Yolitz, Jason¹ (AUTHOR), Licavoli, Isabella¹ (AUTHOR), Wei, Danlan¹ (AUTHOR), Huang, Dawei⁵ (AUTHOR), Soares, Marcelo A.^4,6 (AUTHOR), Martinelli, Elena⁷ (AUTHOR), Cicala, Claudia¹ (AUTHOR), Arthos, James¹ (AUTHOR) jarthos@niaid.nih.gov

Publikováno v: PLoS Pathogens. 12/8/2023, Vol. 19 Issue 12, p1-26. 26p.

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.

Autor: Sordo-Bahamonde, Christian^1,2,3 (AUTHOR), Lorenzo-Herrero, Seila^1,2,3 (AUTHOR), Granda-Díaz, Rocío^2,3,4,5 (AUTHOR), Martínez-Pérez, Alejandra^1,2,3 (AUTHOR), Aguilar-García, Candelaria^1,2,3 (AUTHOR), Rodrigo, Juan P.^2,3,4,5 (AUTHOR), García-Pedrero, Juana M.^2,3,4,5 (AUTHOR), Gonzalez, Segundo^1,2,3 (AUTHOR) segundog@uniovi.es

Publikováno v: Molecular Cancer. 8/30/2023, Vol. 22 Issue 1, p1-15. 15p.